Home › Companies › KYTX

Kyverna Therapeutics

Market cap $297M 63.2M shares (10-Q, Nov 6, 2026) × $4.70 close Nov 17, 2026

Most recent annual filing: 2026-03-26

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. Kyverna Pipeline RA readout2026Kyverna Pipeline RA readout, 2026, notable
  2. Miv-cel (KYV-101) Rheumatoid Arthritis Ph22026Miv-cel (KYV-101) Rheumatoid Arthritis Ph2, 2026, notable
  3. Miv-cel Ph1 readout2026Miv-cel Ph1 readout, 2026, notable
  4. Oxford Term A Loan corporate4Q 2026Oxford Term A Loan corporate, 4Q 2026, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

Ingenui-T · ElevateBio BaseCamp

Proprietary whole blood rapid manufacturing process for CAR T-cell therapies, designed to eliminate apheresis starting material and reduce manufacturing turnaround time; focus on autologous CD19 CAR T for autoimmune diseases

Targets: CD19

Discontinued (1)

Capital (as filed)

Cash
$31.8M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$139M Sep 30, 2026
Operating cash flow
−$35.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$171M cash, runway 2028 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on Kyverna Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Kyverna Therapeutics (KYTX) - Scientific Deep Dive for Miv-Cel and Pipeline Products The science and SPS data are compelling but the author wants clarity on FDA's stance on the BLA before taking a position.
  2. Speculative buy speculative UPDATE: Kyverna Therapeutics (KYTX) - The SPS Receipts Land, And They're Better Than the Topline The KYSA-8 primary analysis retired clinical risk in SPS with a clean registration package, justifying an upgrade from Watch to Speculative Buy, though commercial and manufacturing risks remain.
  3. Buy core UPDATE: Kyverna Therapeutics (KYTX) - The BLA Clock Starts FDA alignment on the single-arm KYSA-8 pivotal removes the largest regulatory tail risk, shifting the story from clinical-stage hope to commercial-stage prep.
  4. Buy core UPDATE: Kyverna Therapeutics (KYTX) - The RA Receipts Land, the Stock Doesn't Care EULAR COMPARE data showing 66.6% ACR70 in refractory RA validates the deep-clean mechanism beyond SPS, and the disconnect between positive reads and the 23.6% stock decline looks like a sentiment/ATM overhang rather than a fundamental problem.
  5. Buy core UPDATE: Kyverna Therapeutics (KYTX) - The Factory Signs a Commercial Lease The five-year ElevateBio commercial supply agreement with a >98% manufacturing success rate de-risks the CMC leg of the SPS BLA, stepping down the 'High' manufacturing risk grade for the SPS launch specifically.
  6. Buy core UPDATE: Kyverna Therapeutics (KYTX) - Three RMATs and the First ATM Draw A third RMAT designation in naSPMS and a filed CMC module extend regulatory de-risking, though the balance sheet has shifted from 'fully funded' to 'funded via levers' and the ATM has now been tapped.
  7. Buy core UPDATE: Kyverna Therapeutics (KYTX) - A Company Doesn't Issue This Press Release on a Quiet Day Kyverna's unsolicited safety reaffirmation (>100 patients, zero high-grade CRS/ICANS, no program pauses) is consistent with the construct-level differentiation argued since March, and nothing in the statement contradicts the five consecutive positive reads since May.
  8. Buy core UPDATE: Kyverna Therapeutics (KYTX) - The Durability Check Clears One-year KYSA-8 data confirm durable SPS benefit (49% T25FW improvement, p<0.0001, 95% of responders sustained) with no new acute safety signals, though the '100% off immunotherapy' headline slipped to 92% and the stock is down 16% on sector sentiment.
  9. Hold UPDATE: Kyverna Therapeutics (KYTX) - The BLA Is In, The Savior Is Shelved The SPS BLA was filed on time with strong durability data, but shelving KYV-102 shrinks the platform thesis to neurology only, the IPO lawsuit survived, and the ATM is being drawn at progressively lower prices, making the risk/reward now dependent almost entirely on FDA acceptance.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (37)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 4, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)